Scot Wolfe is a Professor at UMass Chan Medical School, affiliated with the Department of Molecular, Cell and Cancer Biology. He holds multiple academic roles across institutions including T.H. Chan School of Medicine and Morningside Graduate School of Biomedical Sciences. His research focuses on engineering CRISPR-Cas9 systems for gene therapy, targeting diseases like sickle cell anemia and muscular dystrophy. Wolfe's work emphasizes precision genome editing, delivery systems, and applications in hematopoietic stem cell therapy. Collaborations include projects on HIV latency, zebrafish genomics, and Neurofibromin gene therapy. His lab (wolfe-lab.org) innovates tools like Cas9-ZFP fusions and delivery methods for clinical applications. Education: B.S. from Caltech (1990), Ph.D. from Harvard (1996). Postdoc at MIT. Research spans protein-DNA recognition, zinc finger engineering, and transcription factor specificity. Over 150+ publications focus on gene editing mechanisms and therapeutic applications. Active in the NIH Somatic Cell Genome Editing program. Key projects include enhancing CRISPR specificity, ex vivo editing of HSPCs, and combating genetic disorders via base editing and prime editing. His team develops therapies for beta-hemoglobinopathies, limb-girdle muscular dystrophy, and Hermansky-Pudlak Syndrome. Ongoing work explores HIV cure strategies through proviral inactivation.
Prof. Dr. Michael Sattler is a Full Professor of Biomolecular NMR at the Technical University of Munich (TUM) and Director of the Institute of Structural Biology at Helmholtz Zentrum München. He leads the Molecular Targets & Therapeutics Center and directs the Bavarian NMR Center. His research focuses on integrative structural biology, elucidating molecular mechanisms of biological pathways through advanced NMR techniques combined with cryo-EM, SAXS, and crystallography. Key areas include RNA regulation (alternative splicing, non-coding RNAs), disease mechanisms (e.g., spinal muscular atrophy), and structure-based drug discovery for cancer and infectious diseases. Education & Career PhD in Chemistry (1995) from Goethe University Frankfurt Postdoc at Abbott Laboratories (Chicago) and EMBL Heidelberg (Group Leader, 1997–2007) Full Professor at TUM since 2007 Director roles at Helmholtz Munich and Bavarian NMR Center since 2007 Research Highlights Prof. Sattler's work has revealed structural insights into RNA:protein interactions (e.g., SF1-RNA, U2AF), SMN Tudor domain recognition, and drug discovery strategies targeting Hsp90 and viral proteases. His lab pioneered integrative structural biology approaches and established high-end NMR facilities like the 1.2 GHz spectrometer. Awards & Recognition ERC Synergy Grant (2023) Leopoldina Membership (2017) EMBO Membership (2012) Erwin Schrödinger Prize (2020) Teaching & Leadership He teaches advanced courses in NMR spectroscopy, biochemistry, and structural biology at TUM. Leads EU Horizon-funded training networks (AEGIS, RNAct) and organizes international conferences on NMR and drug discovery.
Dr. Martin F. Semmelhack is a Professor of Chemistry at Princeton University, leading the Semmelhack Lab. His research focuses on designing small molecules to modulate biological processes, particularly bacterial quorum sensing mechanisms in pathogens like Vibrio cholerae and Pseudomonas aeruginosa. His work aims to develop anti-infective drugs by targeting cell communication pathways. Key research areas include synthetic organic chemistry, chemical biology, and bacterial signaling pathways. Notable contributions include the discovery of autoinducers CAI-1 and AI-2, and the development of quorum sensing agonists/antagonists. Collaborations with microbiologists and neuroscientists expand applications into biofilm inhibition and neurotransmitter release technologies. His honors include the Arthur C. Cope Scholar Award (2014), John Simon Guggenheim Fellowship (1978–1979), and Camille and Henry Dreyfuss Teacher-Scholar Grant (1972–1977). Research combines chemical synthesis with biological testing to bridge molecular design and therapeutic potential. Advising and grant activities include funding from the National Institutes of Health and National Science Foundation, supporting interdisciplinary projects. The Semmelhack Lab is located in the Frick Laboratory, Princeton University.
Jan de Hoon serves as a full Professor at KU Leuven's Faculty of Medicine within the Department of Clinical Pharmacology and Pharmacotherapy. He holds dual leadership roles as Head of both the Subdivision and Division of Clinical Pharmacology, and is an active member of the Department of Pharmaceutical and Pharmacological Sciences. His institutional affiliations include membership on the Ethics Committee for Research at UZ/KU Leuven, the Council of the Faculty of Medicine, the POC Geneeskunde, and the Departmental Council. His research centers on TRP channel mechanisms in pain pathways and chemotherapy-induced peripheral neuropathy (CIPN), with significant translational focus from bench to bedside. Key projects include Targeting TRP channels to relief pain (2023-2027) and TRP - Tackling the Roots of Pain (2021-2025). His recent publications demonstrate expertise in neurovascular pharmacology, PET ligand development, and vascular biomarkers for TRP channel functionality. Analysis of his 2024-2025 publications reveals strong emphasis on TRP channel subtypes (TRPA1, TRPV1, TRPM3) in pain mechanisms, vascular readouts for drug effects, and translational models bridging preclinical findings to clinical applications in oncology and neurology. His work frequently employs human tissue studies, healthy volunteer trials, and cancer patient cohorts. As an academic leader, he supervises doctoral candidates including H. Marynissen (2024 thesis on TRP channels in CIPN) and contributes to medical education through courses in Pharmacology, Pharmaceutical Medicine, and Internal Medicine supplements. His research is supported by multiple active grants focusing on TRP channel therapeutics and biomarker development.
Xue Han is a Professor of Biomedical Engineering at Boston University (BU), affiliated with the Han Lab. His primary academic appointment is in the Biomedical Engineering department, with additional affiliations in Neuroscience & Neuroengineering, and Photonics & Optical Systems. He holds a PhD in Physiology from the University of Wisconsin-Madison and a B.S. in Biophysics from Beijing University, China. Dr. Han’s research focuses on addressing unmet medical needs in brain disorders by developing novel neuromodulation therapies. His work combines genetic, molecular, pharmacological, optical, and electrical tools to study neural circuit dynamics, with a particular emphasis on optogenetics and optical neural modulation. Key projects include pioneering light-based neuron silencing techniques and pre-clinical testing of neurotechnologies like transcranial ultrasound stimulation. His lab investigates how neural synchrony contributes to cognition and pathology, aiming to link neural activity to behaviors like movement, attention, and decision-making. His recent publications emphasize high-frequency electrical stimulation effects, membrane voltage imaging, and the impact of neuromodulation on brain rhythms. Notable themes include the role of PV neurons in cortical coding, ultrasound-based neuron activation, and the interplay between neural oscillations and disease states. While no formal awards are listed, his prolific output highlights contributions to neurotechnology and systems neuroscience. Dr. Han’s lab develops advanced imaging tools like targeted-illumination confocal microscopy (TICO) and collaborates on projects involving exosome-mediated therapies and brain-computer interfaces. Ongoing work explores translational applications of neurophotonic tools and the mechanistic basis of neuromodulation therapies for disorders like Parkinson’s and epilepsy.
Lorenzo Alberio is a full professor at the University of Lausanne (UNIL), Faculty of Biology and Medicine, and serves as head physician at the Central Hematology Department and Laboratory of the Lausanne University Hospital (CHUV). He has held academic and clinical leadership roles since joining UNIL in 2014 and was promoted to full professor in 2024. His educational background includes a medical degree (1990) and doctorate (1993) from the University of Bern, FMH in internal medicine (1996), and specialist qualifications in hematology (1999) and analytical hematology (2002). He completed research training at the University of Oklahoma (1997–1999). Alberio's research focuses on hemostasis , platelet function , and coagulation disorders . His work includes the development of flow cytometry techniques and assays for procoagulant platelets (COATs), heparin-induced thrombocytopenia, and thrombin generation. His publications span high-impact journals and cover translational and clinical hematology, with a strong emphasis on diagnostic innovation and therapeutic applications. His recent articles reflect a consistent trend in thrombosis , platelet biology , and anticoagulation strategies , often in the context of cancer and critical care. The work bridges basic science with clinical implementation. Scientific awards include: Johann-Lukas-Schönlein Prize (2000) Multiple distinctions from the Swiss Society of Hematology Alberio is deeply committed to education and mentorship, having developed the Lausanne School of Hemostasis and actively teaching at undergraduate and postgraduate levels. He has secured significant research funding from the Swiss National Science Foundation (SNSF) and leads interdisciplinary projects. His research group operates within the Hemostasis & Platelet Research Laboratory at CHUV, part of a broader network including units in blood cancer proteostasis, targeted immunotherapies, and regenerative hematopoiesis. He maintains international collaborations with institutions in Strasbourg, Tübingen, Islamabad, Leuven, Ghent, and Maastricht. He is also President of the GTH Congress (2021, 2025), underscoring his global academic leadership.
Dr. Jae Ho Lee is a research scientist at Newcastle University specializing in stem cell biology and cancer research, with significant publications between 2006-2010 primarily in collaboration with Professor Karim Nayernia and colleagues including Dr. Ingrid Ehrmann and Professor David Elliott. His work bridges molecular oncology, reproductive biology, and regenerative medicine through investigation of stem cell mechanisms in germ cell development and tumorigenesis. His core research examines stem cell plasticity in cancer and reproduction, focusing on Piwil2 protein functions in breast cancer stem cell proliferation/antiapoptosis, derivation of germ cells from bone marrow stem cells, and spermatogonial stem cell regulation. Key contributions include demonstrating Piwil2's role in Stat3/Bcl-XL-mediated tumor survival, in vitro production of functional male gametes from embryonic stem cells, and transdifferentiation pathways between somatic and germ cells. Analysis of his 2006-2010 publications reveals consistent exploration of molecular intersections between stem cell self-renewal and oncogenesis, with emphasis on Piwil2 as a regulatory hub. His work demonstrates translational potential for infertility treatments through germ cell derivation techniques and identifies apoptosis pathways as therapeutic targets in breast cancer. No scientific awards were documented in the source materials. While specific student mentorship isn't listed, his collaborative publications with senior researchers indicate active laboratory leadership in stem cell projects. The consistent co-authorship with Professor Nayernia suggests participation in grant-funded research programs focused on germ cell biology and cancer stem cells, though exact funding sources remain unspecified.
Prof. Chris Meier is a distinguished Professor of Organic Chemistry at the University of Hamburg, Germany, where he leads the research group AG Meier within the Institute of Organic Chemistry, Department of Chemistry, Faculty of Mathematics, Informatics and Natural Sciences (MIN Faculty). With over two decades of academic leadership, he serves as Co-Speaker of Collaborative Research Center 1648 "Emerging Infections" and has held significant roles including Scientific Director of the Centre for Structural Systems Biology (CSSB) and President of the International Society for Nucleosides, Nucleotides and Nucleic Acids (IS3NA). Dr. Meier's educational background includes a Chemistry degree (Dipl. Chem.) from the University of Marburg/Lahn (1982-1987), followed by his doctorate in Organic Chemistry from the same institution (1987-1989). He completed postdoctoral research at the Pasteur Institute in Paris (1990-1991) and habilitated at Goethe University Frankfurt (1996) before his appointment as C4/W3 Professor at the University of Hamburg in 1999. Professor Meier's research program focuses on nucleoside and nucleotide chemistry, with particular emphasis on pronucleotide development, antisense oligonucleotide chemistry, and stereoselective synthesis of carbocyclic nucleoside analogs. His laboratory investigates molecular mechanisms of chemical carcinogenesis through synthesis of arylamine-modified oligonucleotides and develops innovative organic synthesis methods based on solid support. The group's work bridges fundamental organic chemistry with biomedical applications, particularly in antiviral and anticancer drug development. Recent publications highlight advancements in TriPPP ro -technology for nucleoside triphosphate delivery and metabolic labeling applications. 2018: Antonín Holý Memorial Award from the International Society for Antiviral Research (ISAR) 2007: William Prusoff Award from ISAR 1995: Adolf-Messer Prize for Interdisciplinary Research 1992-1996: Habilitation Scholarship from the German Research Foundation (DFG) 1990-1992: Liebig Postdoctoral Fellowship Professor Meier has successfully mentored numerous doctoral students and postdoctoral researchers, many of whom have gone on to establish independent research careers. His laboratory maintains active collaborations with virology and immunology groups across Europe, particularly with institutions in France (Pasteur Institute, University of Aix-Marseille) and Belgium (KU Leuven). The group has secured substantial funding through multiple Collaborative Research Centers (SFBs) and has developed several patented technologies related to pronucleotide delivery systems. The Meier laboratory operates state-of-the-art organic synthesis facilities within the Institute of Organic Chemistry and maintains close ties with the Centre for Structural Systems Biology (CSSB), where they utilize advanced imaging and structural biology techniques to characterize their compounds. The research group actively participates in the International Society for Antiviral Research and contributes to the development of novel antiviral strategies through both basic research and translational applications.
Dr. Le Lu serves as Researcher & Senior Director leading global Medical AI R&D efforts at Alibaba DAMO Academy since August 2021. His career spans prestigious institutions including the National Institutes of Health, Clinical Center, Radiology and Imaging Science Department, NVIDIA AI-Infra division, and Siemens corporate research where he was a senior staff scientist from 2006 until 2013. Ph.D. in Computer Science from Johns Hopkins University (2007) Dr. Lu specializes in medical imaging AI with significant contributions to oncology imaging and computer vision applications in healthcare. His research bridges advanced AI techniques with clinical applications, particularly in cancer screening and diagnostic imaging. He has published over 250 peer-reviewed articles in top-tier journals including Nature Medicine, Nature Communications, and IEEE Transactions on Pattern Analysis and Machine Intelligence, with more than 23,880 citations as of January 2024. Dr. Lu has received numerous accolades including IEEE Fellowship and recognition for publishing the most cited papers in IEEE TMI and CVPR medical imaging categories over the past decade. His innovative work has resulted in over 100 patent filings across multiple jurisdictions. IEEE Fellow (Computer Society) for contributions to medical imaging, AI and oncology imaging IEEE Signal Processing Society Distinguished Industrial Speaker (2021-2023) Associate Editor for IEEE Trans. Pattern Analysis and Machine Intelligence (IF: 24.3) Associate Editor for IEEE Signal Processing Letters and Frontiers in Oncology MICCAI society board member Through his leadership at Alibaba DAMO Academy, Dr. Lu directs research initiatives focused on making AI-driven healthcare solutions accessible globally, with recent presentations on 'AI for Health for All' and cancer screening paradigms.
Laura Dassama is an Assistant Professor at Stanford University with appointments in both the Department of Chemistry and Department of Microbiology & Immunology . She is actively affiliated with multiple interdisciplinary institutes including Bio-X , SPARK at Stanford , MCHRI , Sarafan ChEM-H , and Wu Tsai Neurosciences Institute . PhD in Biochemistry and Molecular Biology from Pennsylvania State University (2013) Postdoctoral training at Northwestern University (Molecular Biosciences, 2017) Research Associate position at Boston Children's Hospital/Harvard Medical School/Dana-Farber Cancer Institute (2018) Laboratory research focuses on chemical biology approaches to understand biomolecular interactions, particularly bacterial lipid trafficking and targeted protein degradation . Key methodologies include bioinformatic analyses , structural studies , and machine learning algorithms like SLiPP for lipid-binding pocket prediction. Recent publications emphasize antimicrobial resistance challenges and opportunities, protein delivery systems for erythroid cells, and structure-function relationships in lipid transport proteins. These studies demonstrate innovative approaches to address therapeutic limitations through chemical biology tools and interdisciplinary methods . MAC3 Impact Philanthropies Faculty Fellow (2023-2025) Terman Faculty Fellowship (2022-2025, 2018-2021) Hellman Faculty Scholar (2019-2020) Gabilan Junior Faculty Fellowship (2018-2021) Active advisor to multiple PhD candidates and postdoctoral researchers , with formal advising roles in Biophysics , Cancer Biology , and Microbiology & Immunology graduate programs. Laboratory located at Rm. W215 ChEM-H/Neuro Research Complex .
Dr Katherine S Bridge serves as Lecturer in the Department of Biology at the University of York, leading the Bridge Lab within the Centre for Blood Research. Awarded the Kay Kendall Leukaemia Fund Intermediate Fellowship in 2021 and previously holding a Centre for Future Health fellowship (Wellcome Trust ISSF), her research investigates context-dependent roles of Hypoxia Inducible Factor (HIF) in cancer progression and hematopoiesis. Her academic foundation includes: PhD in Molecular Mechanisms of HIF from University of Nottingham Bridge's laboratory examines HIF's dual oncogenic/tumor-suppressive functions across solid tumors and hematological malignancies, with particular focus on non-hypoxic activation pathways in hematopoietic stem cells. Current work identifies molecular switches determining HIF functionality to develop targeted therapeutic interventions for treatment-resistant cancers. Publication trends reveal consistent mechanistic exploration of HIF-LIMD1 interactions since 2012, evolving from foundational degradation studies to feedback loop analyses in tumor microenvironments (2018) and RNA regulatory networks (2017), demonstrating expanding expertise from solid cancers to blood malignancies. Key recognitions: Centre for Future Health fellowship (Wellcome Trust ISSF, 2019) Kay Kendall Leukaemia Fund Intermediate Fellowship (2021) As principal investigator, Bridge mentors postdoctoral researchers including Dr David Kealy and secures major grants like the MRC-funded 'Targeting sodium signalling' project (2023-2026). She actively advocates for parental retention in academia through UKRI's Early Career Researcher forum and Women in Research networks. The Bridge Lab collaborates with York's Centre for Blood Research and international consortia, with Bridge serving on advisory committees for the International Society for Experimental Hematology (2023-2028) and European Haematology Association (2023-2028).
Professor Aideen Sullivan is Head of the Department of Anatomy and Neuroscience at University College Cork (UCC). With a career spanning over two decades at UCC, she leads research on neuroprotective therapies for Parkinson's disease, focusing on growth factors, stem cell applications, and epigenetic mechanisms. She established Ireland's first BSc in Neuroscience and co-developed the cross-College BSc in Medical and Health Sciences (CK707). BSc (First Class Honours) in Pharmacology, University College Dublin (1992) PhD in Neuropharmacology, University of Cambridge (1995) Her research program investigates Parkinson's disease through five key themes: viral vector delivery of neurotrophic factors, molecular mechanisms of neuroprotection, biomarker discovery, neuronal degeneration models, and stem cell-based treatments. She has secured significant grants from Health Research Board, Enterprise Ireland, and the Wellcome Trust. Recent publications (2022-2020) emphasize epigenetic regulation (HDAC inhibitors), microbiome-gut-brain axis interactions, and novel neurotrophic strategies. Articles highlight GDF5's neuroprotective effects, miRNA modulation, and molecular pathways like BMP-Smad and p38-MAPK. Scientific awards include: Postgraduate Certificate in Teaching and Learning (UCC, 2006) FETAC Certificate in Peer-Mentoring (2010) Leadership Foundation Aurora Programme Scholarship (2015) Over €2 million in research grants She mentors undergraduate and postgraduate students, chairs UCC's Athena SWAN 'Flexible Working' group, and serves as Editor-in-Chief of Neuronal Signaling . Her work spans laboratory research, public engagement, and educational innovation.
Professor Graham Ogg is a leading academic at the University of Oxford, where he serves as Professor of Dermatology and leads the Skin Immunology Group. His research focuses on cutaneous immunity, particularly the role of CD1a-restricted T cells in inflammatory skin diseases. He is affiliated with the MRC Human Immunology Unit and MRC Weatherall Institute of Molecular Medicine, driving translational research on lipid antigen presentation and skin immune responses. Professor Ogg's investigations center on molecular mechanisms of skin inflammation, with emphasis on CD1a-mediated T cell activation and its implications for atopic dermatitis, psoriasis, and vaccine development. His work bridges fundamental immunology with clinical applications, exploring how lipid metabolism influences immune pathways in barrier tissues. Research themes include: CD1a-lipid interactions in cutaneous inflammation Therapeutic modulation of skin-specific T cell responses Translational models for dermatological drug delivery Immune mechanisms in allergic skin disorders Analysis of his recent publications (2024-2025) reveals dominant research streams: 1) Clinical dermatology focusing on systemic therapies for atopic eczema, 2) Immunological studies of dengue pathogenesis and metabolic interactions, 3) COVID-19 sequelae and immunity dynamics, and 4) Fundamental T cell biology in autoimmune/inflammatory contexts. This corpus demonstrates interdisciplinary integration of dermatology, virology, and immunometabolism. His scientific recognition includes: Fellowship of the Academy of Medical Sciences (FMedSci) Professor Ogg directs the Skin Immunology Group at the MRC Weatherall Institute, coordinating translational projects that investigate cutaneous immune circuits. The team employs single-cell analysis, spatial transcriptomics, and immunological profiling to dissect skin-specific immune responses, with ongoing work exploring CD1a-targeted therapeutic strategies.
Georgia Marie Beasley is an Associate Professor of Surgery and Medicine at Duke University School of Medicine, with active faculty membership in the Duke Cancer Institute. Her clinical practice focuses on surgical oncology for melanoma treatment, while her research bridges innate immunity and anti-tumor responses. She earned her MD (2008) and MHS in clinical research (2010) from Duke, followed by general surgery residency (2008-2015) and a surgical oncology fellowship at Ohio State University (2015-2017). Education: Duke University School of Medicine (MD, 2008) Duke University (MHS, 2012) Duke University (B.A., 2001) Dr. Beasley's research centers on immunologic aspects of melanoma, particularly oncolytic viral therapy and innate immune mechanisms in tumor response. She leads over 10 therapeutic clinical trials for melanoma, including innovative intratumoral treatments, and has authored more than 100 publications on these topics. Her work explores the intersection of tumor microenvironment dynamics, immune status measurement, and microbiome interactions in cancer progression. Recent publications highlight her focus on circulating tumor DNA applications (2025), GLI2 signaling in immune evasion (2025), and national trends in pediatric stage III melanoma management (2025). These reflect broader research priorities in melanoma staging accuracy, immune-based therapies, and translational oncology. Scientific Awards: Society of Surgical Oncology Young Investigator Award NIH K08 Mentored Physician Scientist Award Melanoma Research Alliance Grant Duke Medical School Alpha Omega Alpha Honor American Society for Clinical Investigation Young Physician-Scientist Award Dr. Beasley secures substantial funding through grants including a 2024-2029 National Cancer Institute award for Duke Research Training in Surgical Oncology, a 2024-2026 NIH grant for older adult melanoma decision-making, and a 2023-2026 Department of Defense grant measuring immune status to prevent recurrence. She also collaborates on training programs at the intersection of cancer immunology and microbiome bioinformatics.
Julie K. Schwarz, MD, PhD, FASTRO is a tenured Professor of Radiation Oncology at Washington University School of Medicine, where she serves as Vice-Chair of Research and Director of the Cancer Biology Division. She also holds appointments as Professor of Cell Biology and Physiology and is affiliated with the Roy and Diana Vagelos Division of Biology & Biomedical Sciences, specifically within the Cancer Biology and Molecular Cell Biology programs. Dr. Schwarz is a key member of the Siteman Cancer Center and co-leads one of only five centers comprising the NIH's Radiation Oncology-Biology Integration Network (ROBIN). Dr. Schwarz completed her BS in Biology at Duke University (1995) followed by an MD/PhD in Cell and Molecular Biology at Washington University School of Medicine (2004) through the Medical Scientist Training Program. She completed her Internal Medicine internship (2005) and Radiation Oncology residency (2009) at Barnes-Jewish Hospital, becoming board-certified by the American Board of Radiology in Radiation Oncology (2010). Her research program focuses on translational studies of gynecologic cancers, particularly cervical cancer, with emphasis on tumor metabolism, biomarker discovery, and treatment resistance mechanisms. Dr. Schwarz's laboratory maintains one of the largest tumor repositories for cervical cancer, which includes specimens collected before and during chemoradiation treatment. Her work has demonstrated the critical role of pretreatment and post-treatment FDG-PET scanning for cervical cancer patients and has identified alterations in PI3K/Akt pathway genes associated with treatment response. Recent research directions include studying obesity's paradoxical favorable impact on cervical cancer outcomes, glucose and glutamine metabolism as targets for cancer therapy, and the role of tumor immunology in therapy resistance. Analysis of Dr. Schwarz's most recent publications reveals a strong focus on cervical cancer biology, tumor metabolism, and novel therapeutic approaches. Her work integrates clinical data with laboratory research to identify biomarkers and develop improved treatment strategies. Current research emphasizes the interface between tumor metabolism, the microenvironment, and response to therapy, with particular attention to HPV-related cancers, tumor imaging, and metabolic targets for radiosensitization. Fellow of American Society for Radiation Oncology (ASTRO) (2024) Danforth WashU Physician-Scientist Scholar Award (2024) Elected into American Society for Clinical Investigation (2022) Michael Fry Research Award for Outstanding Junior Investigator: Radiation Research Society (2012) Fellow: National Cancer Care Network (2008) RSNA Roentgen Resident/Fellow Research Award (2008) As a dedicated mentor, Dr. Schwarz has guided numerous trainees across all levels including undergraduates, graduate students, medical students, residents, fellows, and postdoctoral researchers. Her Schwarz Lab is highly collaborative and actively recruits students and researchers, with recent successes including Leahan Castillo receiving an Honorable Mention at AACR and Brett Tortelli developing significant research on the vaginal microbiome's relationship to cervical cancer treatment response. Dr. Schwarz is R01-funded and leads multiple research projects, including work on the TARGET Center which focuses on understanding the biologic effects of radiation therapy in cancer treatment. She actively participates in national organizations including the ASTRO/NCI Radiobiology Consensus Workshop, AACR Radiation Oncology Think Tank, and the ASTRO Community of Radiation Oncology Physician Scientists. Dr. Schwarz directs the Schwarz Lab, which is growing and actively recruiting postdocs, staff scientists, and graduate students. The lab employs a multidisciplinary approach combining well-annotated clinical databases, prospectively collected patient tumor banks, and state-of-the-art sequencing technologies. Current research directions include single-cell sequencing approaches to study treatment effects on tumor cells and immune cells within the tumor microenvironment, glucose and glutamine metabolism as targets for cancer therapy, and targeting myeloid-derived cells to improve anti-tumor immunity. The lab is highly collaborative and studies multiple tumor types including cervical, pancreatic, and ovarian cancers.
